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Abstract
Experimental and clinical experiences highlight the need to review some aspects of islet transplantation, especially
with regard to site of grafting and control of the immune response. The subcutaneous space could be a good
alternative to liver but its sparse vasculature is its main limitation. Induction of graft tolerance by using cells with
immunoregulatory properties is a promising approach to avoid graft rejection. Both Fibroblasts and Mesenchymal
Stem Cells (MSCs) have shown pro-angiogenic and immunomodulatory properties. Transplantation of islets into the
subcutaneous space using plasma as scaffold and supplemented with fibroblasts and/or Bone Marrow-MSCs could
be a promising strategy to achieve a functional extra-hepatic islet graft, without using immunosuppressive drugs.
Xenogenic rat islets, autologous fibroblasts and/or allogenic BM-MSCs, were mixed with plasma, and coagulation
was induced to constitute a Plasma-based Scaffold containing Islets (PSI), which was transplanted subcutaneously
both in immunodeficient and immunocompetent diabetic mice. In immunodeficient diabetic mice, PSI itself allowed
hyperglycemia reversion temporarily, but the presence of pro-angiogenic cells (fibroblasts or BM-MSCs) within PSI
was necessary to improve graft re-vascularization and, thus, consistently maintain normoglycemia. In
immunocompetent diabetic mice, only PSI containing BM-MSCs, but not those containing fibroblasts, normalized
glycemia lasting up to one week after transplantation. Interestingly, when PSI contained both fibroblasts and BM-
MSCs, the normoglycemia period showed an increase of 4-times with a physiological-like response in functional
tests. Histology of immunocompetent mice showed an attenuation of the immune response in those grafts with BM-
MSCs, which was improved by co-transplantation with fibroblasts, since they increased BM-MSC survival. In
summary, fibroblasts and BM-MSCs showed similar pro-angiogenic properties in this model of islet
xenotransplantation, whereas only BM-MSCs exerted an immunomodulatory effect, which was improved by the
presence of fibroblasts. These results suggest that cooperation of different cell types with islets will be required to
achieve a long-term functional graft.
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Introduction
The current standard therapy for type 1 diabetes mellitus
fails to achieve physiological control of blood glucose,
increasing the risk of long-term diabetic complications.
Pancreatic islet transplantation could be one of the alternatives
to treat definitively type 1 diabetes, nevertheless, current
protocols of clinical islet transplantation have not yielded long-
term insulin-independence [1]. The experimental and clinical
experiences highlight the need to review some aspects of islet
transplantation protocol, especially with respect to the site of
transplantation and the control of the intrinsic immune
response [2].
The liver has been chosen as the reception site in clinical
islet transplantation. However, experimental and clinical studies
have shown several factors that indicate that the liver seems
not to be the optimal place for islet grafts [3–5]. For this reason,
alternative sites have been proposed such as spleen, renal
capsule, testes, brain, peritoneal cavity, omentum, bone
marrow, muscle, epididymal fat or the subcutaneous space
[6–8]. The subcutaneous space constitutes a very attractive
site of transplantation because it would provide a simple and
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safe procedure. Nevertheless, the sparse vasculature of this
tissue restricts blood supply to the graft, which becomes
essential for both islet survival and function during the first days
after transplantation [9]. In addition, blood supply, is also
especially important for restoring islet-extracellular matrix
interactions affected by the islet isolation procedure [10,11].
Most of the attempts to overcome these great limitations have
focused on the use of different biomaterials as scaffolds either
alone or in combination with pro-angiogenic factors [12–15].
Control of the immune response has been tested in several
approaches, with or without immunosuppressive drugs.
Diffusion chambers or micro and macrocapsules, are devices
that have been tried, wit the aim of providing enough oxygen
flow while maintaining a barrier to immune cells [16]. Induction
of graft tolerance by using cells with immunoregulatory
properties is a promising approach to avoid graft rejection that
has emerged in recent years. The beneficial effect of
multipotent mesenchymal stem cells (MSCs) in transplant
approaches has been recently attributed to its capacity in
producing several factors with paracrine immunomodulatory
properties [17,18]. Through secretion of these factors, mainly
transforming growth factor (TGF)-β1, hepatic growth factor
(HGF), nitric oxide, indoleamine 2,3-dioxygenase (IDO),
prostaglandin E-2 (PGE-2), matrix metalloproteinase (MMP) -2
and -9 or interleukin (IL) -6, MSCs they are able to regulate
both innate and adaptive immune response, controlling
proliferation, migration and function of both B, T and NK cells,
as well as inhibiting immunoglobulin and antibody production,
dendritic cells maturation and neutrophils activation [19]. These
cells have being used in clinical trials of “graft versus host
disease” and autoimmune disease treatment with promising
results [20] and are being evaluated in solid organ
transplantation phase I/II clinical trials [21]. Regarding
fibroblasts, direct comparison between adult fibroblasts from
various tissues and bone marrow MSC showed similar in vitro
immunosuppressive potency [22–24].
We have recently published a novel model of subcutaneous
islet transplantation using a biodegradable plasma-based
scaffold containing fibroblasts allowing long time graft survival
in immunodeficient mice [25]. Taking into account their
described properties, we explored whether the presence of
autologous fibroblasts and/or allogenic BM-MSCs in our
Plasma-based Scaffold containing Islets (PSI) could induce
graft tolerance after subcutaneous transplantation in an
immunocompetent recipient, improving graft viability, without
using immunosuppressive drugs.
Materials and Methods
Animals and Ethics Statement
Twelve-week-old male Wistar rats (Animal Facilities,
University of Oviedo, Spain) were used as pancreatic islet
donors. Six-week-old male Swiss nu/nu mice (Harlan Iberica,
Barcelona, Spain) were used as immunodeficient recipients.
Six-week-old male mice from the commercial luminescent
strain FVB/N-Tg (β-Actin-luc)-Xen mice (Caliper Life Sciences,
Hopkinton, MA) were used as source of luminescent (Luc[+])
cells (fibroblasts or BM-MSCs). Six-week-old male non-
bioluminescent (Luc[-]) mice from the FVB/N-Tg (β-Actin-luc)-
Xen mice strain (Caliper Life Sciences) were used as
immunocompetent recipients. Mice were rendered diabetic by a
single intraperitoneal injection of streptozotocin (STZ) (225
mg/kg body weight; Sigma-Aldrich, Madrid, Spain). Diabetes
was defined as non-fasting blood glucose (NFBG) levels higher
than 450 mg/dL determined in two consecutive days [26].
Experiments were conducted in accordance with the guidelines
of the European Union (86/609/EU) and Spanish regulations
(BOE 67/8509-12, 1988). Experimental protocols were also
approved by the Committee for Animal Care and Handling of
the University of Oviedo (Permit number: 9-INV-2004). All
surgery was performed under xylazine-ketamine anesthesia
and animals were sacrificed using CO2. All efforts were made
to minimize animal suffering and to reduce the number of
animals used.
PSI preparation and transplantation
Plasma.  Blood was obtained from Wistar rats by
venipuncture into 5-mL sodium citrate-coated sterile tubes
(Vacutainer SST™ II Advance; Becton-Dickinson, Plymouth,
United Kingdom) and centrifuged at 3000 rpm for 15 min. The
plasma was collected and frozen until use.
Pancreatic islets were obtained as previously described [27].
Wistar rat pancreata were distended with an intraductal
injection of collagenase type XI (Sigma-Aldrich). The pancreata
were then harvested, incubated in a water bath at 37 °C for 21
min, and the digested tissue washed in Hank’s balanced salt
solution (HBSS, Sigma-Aldrich). Islets were separated by
Dextran (Sigma-Aldrich) discontinuous density gradient
centrifugation, washed in HBSS, and immediately prepared for
transplant. Islet equivalents (IEQs), purity, and viability were
calculated by examining dithizone-stained (Sigma-Aldrich)
preparations.
Skin fibroblasts were obtained autologously (from nu/nu or
FVB/N-Tg (β-Actin-luc)-Xen mice) as previously described [25].
Full-thickness skin biopsy specimen (1cm2) from the right flank
was ground without previous dermis-epidermis separation, and
the homogenate subjected to enzyme digestion with 2 mg/mL
collagenase (Sigma-Aldrich) at 37 °C for 4 h. The digested
tissue suspension was then filtered through a cell strainer
(Becton Dickinson) and centrifuged at 1400 rpm for 10 min.
The resultant pellet was resuspended in Dulbecco’s modified
Eagle’s medium (DMEM, Lonza, Basel, Switzerland)
supplemented with 10% fetal calf serum (Gibco Invitrogen,
Paisley, United Kingdom) and Antibiotic-Antimycotic solution
(50 U/ml penicillin + 50 µg/ml streptomycin, Gibco Invitrogen),
and cells were seeded in culture flasks and cultured at 37 °C in
a humidified atmosphere of 5% CO2. Fibroblasts were used
after 4–5 passages.
BM-MSCs.  Isolation of MSCs from nu/nu (immunodeficient
experiments) or FVB/N-Tg (β-Actin-luc)-Xen mice
(immunocompetent experiments) was carried out according to
Soleimani M. et al [28] with some modifications. Briefly, bone
marrow was collected by flushing femurs and tibias with
complete medium: DMEM/Ham’s F12 medium (Lonza) + 20%
fetal calf serum + Antibiotic-Antimycotic solution (50 U/ml
penicillin + 50 µg/ml streptomycin, Gibco Invitrogen),
Fibroblasts and BM-MSCs in Islet Transplantation
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supplemented with 5 U/mL heparin (Hospira Prod. Farm. SL,
Madrid, Spain). Bone marrow cells were washed once with
PBS, resuspended in complete medium and seeded in culture
flasks to be cultured at 37 °C in a humidified atmosphere of 5%
CO2. BM-MSCs were used after 4-5 passages. In order to
check pluripotency maintenance of these cells, osteogenic and
adipogenic differentiation were verified by alkalyne
phosphatase and oil red o staining, respectively (data not
shown).
PSI preparation.  Cultured cells (fibroblasts, BM-MSCs or
both) were resuspended in plasma containing 5 mg/mL of
tranexamid acid (Amchafibrin, Fides-Ecofarm, Barcelona,
Spain). Next, 1500 fresh IEQs, obtained from two donor rats,
were added to the mixture and the final volume was adjusted to
4 mL with DMEM + 6.75 mM CaCl2. The mixture was finally
allowed to solidify for 15-20 minutes. Purity and viability of the
islet samples used were not significantly different between the
experimental groups (data not show).
PSI transplantation.  Transplantation was performed in
diabetic mice 7-10 days after STZ injection. Mean pre-
transplant NFBG of mice, as well as purity and viability of the
islet samples used, were similar in all groups. PSI was placed
directly over the abdominal musculature after performing a skin
incision. NFBG was monitored periodically after transplantation
on whole blood samples obtained from the tail vein.
Normoglycemia was defined as a NFBG level <200 mg/dL.
Experimental groups
Unless mentioned, five animals were used in each
experimental group.
Immunodeficient model.  For graft function studies, the
following groups were used: diabetic mice transplanted with
free islets (ISC), PSI without cells (PSI), PSI containing 2x105
autologous fibroblasts (PSI-F), PSI containing 2x105 allogenic
BM-MSCs (PSI-M) and PSI containing 2x105 of both
autologous fibroblasts and allogenic BM-MCSs (PSI-FM), as
well as non-transplanted diabetic animals and non-transplanted
healthy animals.
For cell evolution studies by bioluminescence follow-up, the
following groups were performed: diabetic mice transplanted
with PSI containing 106 allogenic Luc[+]-fibroblasts (PSI-5Fluc),
PSI containing 106 allogenic Luc[+]-BM-MSCs (PSI-5Mluc) or
PSI containing 106 of mixed autologous Luc[-]-fibroblasts and
allogenic Luc[+]-BM-MSCs (PSI-5FMluc).
Immunocompetent model.  For graft function studies, the
following groups were used: diabetic mice transplanted with
free islets (ISC), PSI without cells (PSI), PSI containing
autologous fibroblasts (PSI-F), PSI containing allogenic BM-
MSCs (PSI-M), or PSI containing mixed autologous fibroblasts
and allogenic BM-MSCs (PSI-FM), as well as non-transplanted
diabetic animals and non-transplanted healthy animals. Three
different numbers of cells were added to PSI: 2x105, 4x105 and
106 of each cell type.
For cell evolution studies by bioluminescence follow-up, the
following groups were performed: diabetic mice transplanted
with PSI containing 106 allogenic Luc[+]-BM-MSCs (PSI-5Mluc)
or with PSI containing 106 of mixed autologous Luc[-]-
fibroblasts and allogenic Luc[+]-BM-MSCs (PSI-5FMluc).
Intraperitoneal glucose tolerance tests (IPGTTs)
After an overnight fast, the animals received an
intraperitoneal glucose bolus (2 g/Kg of body weight) as a 5%
solution in Hanks’ Balanced Salt Solution (Lonza), and blood
glucose was monitored at 0, 15, 30, 60, 90 and 120 min. To
evaluate the response to IPGTTs, the “area under the curve”
(AUC) was calculated for each animal using the trapezoidal
rule method [29].
In vivo bioluminescence imaging
To monitor regularly the luminescence of Luc[+]-BM-MSCs
or Luc[+]-fibroblasts subcutaneously transplanted in mice, the
IVIS® Lumina (Caliper Life Sciences) in vivo noninvasive
bioluminescence imaging system was used after an
intraperitoneal injection of 150 mg/Kg D-Luciferin (Melford,
Suffolk, United Kingdom) in PBS. Bioluminescence signal was
measured using Living Image® software and normalized to the
day of transplantation.
Histology
In order to analyze histologically the transplanted xenografts,
mice were sacrificed sixty (immunodefficient) or seven
(immunocompetent) days after transplantation. Islet grafts were
fixed in 4% paraformaldehyde for 24 h. After fixation, the
specimens were dehydrated in a graded series of ethanol
dilutions and embedded in paraffin. Sections of 4-µm thick
were obtained using a microtome HM 350 S (Microm, Waldorf,
Germany). Some sections were stained with hematoxylin and
eosin (H&E) for microscopy examination. The presence of
functional islets was confirmed by immunohistochemical insulin
labeling. Briefly, paraffin sections were deparaffinized and
rehydrated in EZ Prep, and placed in Reaction Buffer. The
primary antibody was polyclonal Guinea pig Anti-Insulin (Dako,
Glostrup, Denmark). The reaction was carried out in the
Discovery XT System. Sections were incubated at 37 °C with
primary antibody (1:60) for 1 h in Ab diluent. The secondary
antibody used was OmniMap anti-Rb HRP and detection was
carried out with ChromoMap DAB. Contrast staining was
performed with hematoxylin and bluing reagent. The relative
insulin-positive area was determined on slides (n = 5 per
group). The presence of vessels was confirmed by
immunohistochemical CD-31 labelling using the Discovery XT
System again. After deparaffination and rehydration, sections
were placed in reaction buffer. Unmasking was performed in
standard “CC1” conditions (60 min, 100 °C). Sections were then
incubated at 37 °C with an anti-CD31 polyclonal antibody
(Abcam, Cambridge, United Kingdom), 1:50 for 32 min. The
secondary antibody used was OmniMap anti-Rb HRP and
detection was carried out with ChromoMap DAB. Contrast
staining was performed with hematoxylin and bluing reagent.
Vessel numbers were determined by counting total CD-31
positive vessels in equivalent areas (6 fields per slide, n = 4 per
group) observed on the matrix surrounding islets. Leukocyte
infiltration throughout the islet graft was quantified by the
number of myeloperoxidase (MPO) positive cells. The reaction
was carried out with an anti-MPO antibody (Thermo, Fisher
Scientific, Waltham, MA) also in the Discovery XT System.
First, unmasking was performed by heating at pH 8.4 with CC1
Fibroblasts and BM-MSCs in Islet Transplantation
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buffer. Then, slides were blocked with the casein based
Antibody block and incubated with the antibody at 37 °C, for 1 h
and at a 1:50 dilution in Ab diluent. The next steps were the
same as those described for insulin. The number of MPO-
positive cells in the equivalent areas was determined on slides
(6 fields per slide, n=4 per group). All reagents, except where
specified, were from Ventana, Oro Valley, AZ.
Statistical analysis
Results are expressed as mean ± SEM. The significance of
differences between two independent groups was calculated
using the unpaired Student’s t-test. For multiple comparisons,
ANOVA tests were conducted followed by the Scheffé post hoc
test to determine specific differences between groups, unless
otherwise indicated. A p-value <0.05 was considered
statistically significant.
Results
Immunodeficient model: subcutaneous transplantation
of PSI in diabetic mice
STZ-induced diabetic nude mice (n=5 per group) were
transplanted subcutaneously with xenogenic islets alone (ISC)
or embedded into a plasma-based scaffold without cells (PSI)
or containing 2 x 105 autologous fibroblasts (PSI-F), 2 x 105
allogenic BM-MSCs (PSI-M) or 2 x 105 of both autologous
fibroblasts and allogenic BM-MSCs (PSI-FM).
None of the non-transplanted diabetic mice or mice
transplanted subcutaneously with free islets (ISC) reversed
hyperglycemia (Figure 1A). However, when islets were
transplanted into PSI without cells, mice reversed
hyperglycemia for the first days after transplantation, but were
not able to maintain a stable normoglycemia, showing a
progressive increase of NFBG in subsequent days.
Nevertheless, the presence of fibroblasts (PSI-F), BM-MSCs
(PSI-M) or both (PSI-FM) in the PSI allowed mice to achieve
normoglycemia and to maintain it stably throughout the follow
up, without significant differences between the three groups.
The IPGTT performed 60 days after transplantation showed a
non-physiological glucose tolerance response by PSI mice,
although their function was significant better than that shown
by non-transplanted diabetic mice (Figure 1B and C). Both PSI-
F, PSI-M and PSI-FM mice showed a physiological-like
response, with PSI-F and PSI-FM showing a significantly better
function than PSI-M. Histological study showed insulin-positive
islets completely integrated in a new-formed collagen-like
matrix at the subcutaneous space of PSI, PSI-M, PSI-F and
PSI-FM mice (Figure 1D). Nevertheless, the matrix appeared
more organised and better integrated with adjacent tissues
when fibroblasts, BM-MSCs or both where contained in the
PSI. Vessel counting showed that the presence of fibroblasts,
BM-MSCs or both in the PSI improved graft vascularization
(Figure 1 E). No significant insulin staining was observed in the
pancreata of any of the diabetic mice subjected to
subcutaneous transplantation (data not shown).
Immunocompetent model
Subcutaneous transplantation of PSI in diabetic
mice.  STZ-induced diabetic Luc[-] mice were transplanted
subcutaneously with xenogenic islets alone (ISC, n=5) or
embedded into a PSI without cells (PSI, n=5) or containing:
autologous fibroblasts (PSI-F), allogenic BM-MSCs (PSI-M), or
autologous fibroblasts + allogenic BM-MSCs (PSI-FM). In each
group, three different numbers of cells were studied: 2 x 105
(n=5), 4 x 105 (n=5) and 106 (n=7).
None of ISC or PSI mice were able to reverse hyperglycemia
(data not shown) not even when fibroblasts were added to PSI
(PSI-F mice) (Figure 2A). However, when fibroblasts were
substituted with BM-MSCs (PSI-M), hyperglycemia was
reversed in the first two days after transplantation, although
normoglycemia was only maintained for a mean period of 4 ±
1.1 days (Figure 2B). No cell dose-effect was observed in
either PSI-F (Figure 2A) or PSI-M mice (Figure 2B).
Interestingly, when both autologous fibroblasts and allogenic
BM-MSCs were co-transplanted into PSI (PSI-FM),
normoglycemia was also achieved in the first two days after
transplantation but, in this case, maintained for a mean period
of 7.2 ± 0.5 days (Figure 2C). Moreover, the increase of the
number of both BM-MSCs and fibroblasts co-transplanted
together in the PSI showed a clear cell-dose effect. By doubling
the cell number of both cell types (PSI-2FM), normoglycemia
was maintained 11.6 ± 3.04 days after transplantation (with one
mouse maintaining normoglycemia until day 20), while when
increasing 5-fold the cell number (PSI-5FM), normoglycemia
was maintained 18.4 ± 3.86 days after transplantation (with one
mouse maintaining normoglycemia until day 30) (Figure 2D
and Table 1).
To further study the functional efficacy of the islet xenografts,
IPGTTs were performed in the three groups transplanted with
the highest dose of cells (PSI-5F, PSI-5M and PSI-5FM), seven
days after transplantation. Day seven was chosen since
maximum NFBG differences within these groups were
observed. IPGTT for PSI-5F mice was similar to control
diabetic mice (data not shown), in accordance with their high
NFBG throughout the study. In the same way, mice
Table 1. Period of normoglycemia after subcutaneous
transplantation of PSI in diabetic immunocompetent mice.
Group n Days of normoglycemia
PSI + 106 BM-MSCsalo 7 4.2 ± 1.07a
PSI + 2x 105 BM-MSCsallo and 2 x 105
fibroblastsauto
5 7.2 ± 0.49b
PSI + 4x 105 BM-MSCsallo and 4 x 105
fibroblastsauto
5 11.6 ± 3.04
PSI + 106 BM-MSCsallo and 106 fibroblastsauto 7 18.4 ± 3.86
a p<0.05 versus all groups.
b p<0.05 versus PSI + 106 BM-MSCsallo and 106 fibroblastsauto
ANOVA of data followed by the Scheffé post hoc test
All results are expressed as mean ± SEM.
PSI, plasma-based scaffold containing xenogenic islets; BM-MSCsallo, allogenic
bone marrow-mesenchymal stem cells; fibroblastsauto, autologous skin fibroblasts
Fibroblasts and BM-MSCs in Islet Transplantation
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Figure 1.  Subcutaneous transplantation of PSI in immunodeficient diabetic mice.  A) Follow up of NFBG in the following
groups: (○) non-transplanted mice; (♦) mice subcutaneously transplanted with free islets (ISC); (●) mice subcutaneously
transplanted with PSI; (■) mice subcutaneously transplanted with PSI containing 2x105 allogenic BM-MSCs (PSI-M); (▲) mice
subcutaneously transplanted with PSI containing 2x105 autologous fibroblasts (PSI-F); (□) mice subcutaneously transplanted with
PSI containing 2x105 of both autologous fibroblasts and allogenic BM-MSCs (PSI-FM). B) Blood glucose responses to IPGTTs, 60
days after transplantation. Groups are the same as detailed in A except for (◊) non-transplanted healthy mice. C) AUC data obtained
from IPGTTs. D) Histology of subcutaneous islet xenografts 60 days after transplantation in hematoxylin and eosin stained samples.
Black arrows point to islets and red arrows point to vessels. E) Quantification of vessels in the subcutaneous grafts after CD31
immunostaining. For all groups n=5. Statistical significances (p<0.05): (a) ISC and diabetic vs the other groups; PSI vs PSI-M, PSI-F
and PSI-FM; (b) PSI vs PSI-M, PSI-F and PSI-FM. (*) p<0.05; (**) p<0.01.
doi: 10.1371/journal.pone.0073526.g001
Fibroblasts and BM-MSCs in Islet Transplantation
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transplanted with PSI containing BM-MSCs (PSI-5M) showed a
diabetic-like response, in spite of their lower NFBG when
compared to that of PSI-5F mice (Figure 2E). Mice
transplanted with both BM-MSCs and fibroblasts (PSI-5FM)
showed a physiological-like response, with a blood glucose
tolerance significantly better than PSI-5M (Figure 2F). In spite
Figure 2.  Subcutaneous transplantation of PSI in immunocompetent diabetic mice.  A) Follow up of NFBG in mice
subcutaneously transplanted with PSI containing three different cell doses of autologous fibroblasts: 2 x 105 (PSI-F, n=5), 4 x 105
(PSI-2F, n=5) and 1 x 106 (PSI-5F, n=7). B) Follow up of NFBG in mice subcutaneously transplanted with PSI containing three
different cell doses of allogenic BM-MSCs: 2 x 105 (PSI-M, n=5), 4 x 105 (PSI-2M, n=5) and 1 x 106 (PSI-5M, n=7). C) Follow up of
NFBG in mice transplanted with PSI containing three different cell doses of both autologous fibroblasts and allogenic BM-MSCs: 2 x
105 (PSI-FM, n=5), 4 x 105 (PSI-2FM, n=5) and 1 x 106 (PSI-5FM, n=7). All results are expressed as mean ± SEM. Statistical
significances (p<0.05): (a) PSI-5FM vs PSI-FM and PSI-2FM; (b) between the three groups; (c) PSI-2FM vs PSI-5FM. D) Percentage
of animals with normoglycemia after transplantation. Thick line, PSI-5F; dotted line, PSI-5M; thin line, PSI-5FM. E) Blood glucose
responses to IPGTTs performed 7 days after transplantation in the following groups of diabetic mice: (♦), non-transplanted; (▲),
PSI-5M; (●), PSI-5FM; (■), non-transplanted healthy mice. For all groups n=7. F) AUC data obtained from IPGTTs. (*) p<0.05; (***)
p<0.001.
doi: 10.1371/journal.pone.0073526.g002
Fibroblasts and BM-MSCs in Islet Transplantation
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of a good glucose tolerance, a significant difference was also
observed when comparing PSI-5FM with healthy control mice.
In vivo follow-up of cells transplanted subcutaneously in
the PSI.  Behaviour and viability of allogenic Luc[+]-BM-MSCs
embedded in PSI and transplanted subcutaneously in
immunocompetent mice (n=5 per group), was addressed by
determining in vivo bioluminescence. The bioluminescence of
BM-MSCs transplanted alone in PSI (PSI-5Mluc) showed a
marked decrease after transplantation, with only 6.2%
remaining at day 12 (Figure 3A). In contrast, bioluminescence
of BM-MSCs subcutaneously co-transplanted with autologous
Luc[-]-fibroblasts in PSI (PSI-5FMluc), increased markedly 2
days after transplantation, and decreased during subsequent
days. In spite of this, the bioluminescence of BM-MSCs co-
transplanted with fibroblasts was always significantly higher
than that of BM-MSCs transplanted alone.
To check whether a possible immunological effect could
explain the reduced survival of allogenic BM-MSCs,
subcutaneous transplantation was performed in
immunodeficient mice (n=5 per group). Bioluminescence of
Luc[+]-BM-MSCs transplanted alone in PSI (PSI-5Mluc) also
showed a marked decrease, with 4.27% remaining at day 12
(Figure 3B). When co-transplanted with autologous Luc[-]-
fibroblasts (PSI-5FMluc), a significant increase of BM-MSC
bioluminescence was observed at day 2 after transplantation,
which decreased in the following days. Again, bioluminescence
was still significantly higher than that of BM-MSCs transplanted
alone (PSI-5Mluc). Interestingly, allogenic Luc[+]-fibroblasts
transplanted alone in PSI (PSI-5Fluc) showed a
bioluminescence evolution very similar to that shown by
allogenic Luc[+]-BM-MSCs when co-transplanted with
autologous Luc[-]-fibroblasts (PSI-5FMluc).
Histological examination of subcutaneous islet
xenografts.  Histological analysis of subcutaneous islet
xenografts was performed seven days after transplantation in
diabetic immunocompetent mice (Figure 4). Xenografts of ISC,
PSI without cells or containing autologous fibroblasts (PSI-5F)
showed a great lymphocyte and polymorphonuclear cells
Figure 3.  Evolution of bioluminescent cells embedded in PSI and subcutaneously transplanted in both immunocompetent
and immunodeficient mice.  A) Immunocompetent mice. Relative luminescence signal of 106 allogenic Luc[+]-BM-MSCs
transplanted alone into PSI (PSI-5Mluc) or co-transplanted with 106 autologous Luc[-]-fibroblasts (PSI-5FMluc), as well as
representative IVIS® lumina images of previously described mice, 12 days after transplantation. B) Immunodeficient mice. Relative
luminescence signal of 106 allogenic Luc[+]-BM-MSCs transplanted alone into PSI (PSI-Mluc) or co-transplanted with 106 autologous
Luc[-]-fibroblasts (PSI-FMluc), as well as luminescence signal of 106 allogenic Luc[+]-fibroblasts transplanted alone into PSI (PSI-
Fluc). Representative IVIS® lumina images of previously described mice, 12 days after transplantation. Values related to day 0
(100%) are represented as mean ± SEM. For all groups n=5. (*) p<0.05; (**) p<0.01; (***) p<0.001.
doi: 10.1371/journal.pone.0073526.g003
Fibroblasts and BM-MSCs in Islet Transplantation
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(PMN) infiltration. No insulin-positive cells were observed in
ISC grafts, while PSI and PSI-5F grafts showed small
aggregates of insulin-positive cells, resulting from islet
degradation, surrounded by non-integrated plasma scaffold.
Xenografts containing allogenic BM-MSCs (PSI-5M) showed
less lymphocyte infiltration with a lower number of PMNs.
Some insulin-positive islets were observed, but most of them
showed symptoms of injury like disrupted insulin staining and
irregular morphology. Finally, xenografts containing autologous
fibroblasts and allogenic BM-MSCs (PSI-5FM) showed the
least lymphocyte and PMN infiltration. Furthermore, several
insulin-positive islets were observed, most of them with normal
morphology and continuous insulin staining.
Additionally, we quantified the extension of leukocyte
infiltration by MPO-staining, a valid measure for the extent of
organ rejection [30]. The number of MPO positive cells present
in the PSI-5M xenografts was significantly lower with respect to
that of PSI-F, PSI and ISC mice, and it was even lower in those
transplanted with both BM-MSCs and fibroblasts (PSI-5FM)
(Figure 4B). Likewise, we measured the presence of insulin-
positive areas, which indirectly correlated with MPO-staining,
indicating a higher-maintained islet function when
immunological response was lower (Figure 4C).
Discussion
Two of the main key points of islet transplantation are the
site of engraftment and the control of the immune response.
The subcutaneous space could be a good alternative, but its
main limitation resides in its poor vascularization. In this sense
the pro-angiogenic and immunomodulatory properties of
different cell types, like dermal fibroblasts [22,31] or MSCs
[17,18,32], have been described. The work presented here
shows how islets embedded in a plasma-based scaffold (PSI)
transplanted subcutaneously were able to reverse
hyperglycemia in diabetic immunodeficient mice, although the
presence of BM-MSCs and/or fibroblasts in the graft was a
requirement for maintaining long-term islet function.
Nevertheless, in immunocompetent mice, the presence of
fibroblasts in PSI did not reverse hyperglycemia, while BM-
MSC presence allowed its reversal in all transplanted mice for
a short period of time. Surprisingly, when both cell types were
co-transplanted together into the PSI, a better control of
glycemia was observed, achieving up to one month of
normoglycemia without using immunosuppressive drugs.
Previous reports have shown that fibrin gel, in addition to its
pro-angiogenic properties, supports cell survival, growth and
differentiation through the intermediary function of specific
extracellular matrix proteins [33–35]. Fibrin has also been used
to maintain the three-dimensional configuration of human islets
in vitro, giving rise to a robust functional graft under the kidney
capsule of nude mice [36], and as a carrier for islet
transplantation [37]. In the present work, we have extended
these results demonstrating that subcutaneous transplantation
of islets in diabetic immunodeficient mice reversed
hyperglycemia when embedded in a plasma gel (PSI),
suggesting an active participation of this scaffold as
extracellular matrix [38]. Similarly, as occurred in several
studies in immunodeficient or syngenic models [25,39–41], the
presence of fibroblasts and/or BM-MSCs improved islet
function and viability due to their pro-angiogenic properties,
favouring graft revascularization and normoglycemia
restoration.
Regarding islet transplantation in immunocompetent
recipients, only allogenic BM-MSCs exerted an
immunomodulatory effect at the subcutaneous space.
Nevertheless, this positive effect was only partial towards
glycaemic normalization. A plausible explanation for this result
could be the reduced survival of these cells during the first
days after transplantation, which was observed both in
immunocompetent and immunodeficient mice, pointing to a
non-immunological cause as responsible for this effect. In a
poor vascularized subcutaneous space, it is feasible that
sparse blood supply and low oxygen tension may lead to BM-
MSC loss as has been described under hypoxic conditions and
serum deprivation [42]. In our model, fibroblasts improved islet
and BM-MSCs survival, underlining their pro-angiogenic effect
on graft revascularization and, therefore, reduction of hypoxia
[43]. Unlike BM-MSCs, it has been described that fibroblasts
are cells with a higher tolerance to hypoxia which indeed have
the potential to rapidly proliferate and migrate under hypoxic
conditions, modulating their function to adapt vascular needs
[44,45]. Furthermore, ischemic conditions induce an
overexpression of the pro-angiogenic Hypoxia Inducible
Factor-1 alpha and the pro-survival B-cell lymphoma 2 in
fibroblasts [44,46]. Moreover, some factors secreted by these
cells have been shown to stimulate BM-MSC proliferation [47],
as well as to induce an increase in their survival [48,49].
However, in spite of the MSC-like immunosuppressive
properties attributed to fibroblasts in the literature [50], mainly
demonstrated by in vitro studies, no significant
immunomodulatory effect was observed in our model.
Further studies are needed in order to address the
underlying mechanisms of this cooperation. In this sense, we
are currently performing in vitro studies to compare the
“secretome” of BM-MSCs and Fibroblasts cultured alone or
together, with or without the presence of islets, under hypoxic
or normoxic conditions. Knowing the molecular mechanisms of
this cooperative relationship among fibroblasts, MSCs and
islets, is a required step in order to perform in vivo experiments
to optimize the timing, dose, administration route and
combination of cells and/or different factors in our model.
In this work, the evolution of fibroblasts and BM-MSCs
contained in PSI has been analyzed by luminescent tracking,
which is a commonly used strategy in in vivo cell survival and
proliferation studies [51]. Luminescent data provide useful
information about cell tracing and viability without sacrificing
animals, but must be interpreted carefully since several factors,
such as graft re-vascularization, must been taking into account
due to their influence on the results, especially in the first days
after transplantation [52]. Keeping this in mind, our data shows
for the first time a positive effect of fibroblasts over BM-MSC
proliferation and survival under such restricted conditions as in
the subcutaneous space. As a result, BM-MSCs prolonged
their effect in our system and thus, xenograft viability in the
immunocompetent recipient.
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Figure 4.  Histology of subcutaneous islet xenografts in immunocompetent diabetic mice.  A) Representative images of
subcutaneously transplanted islets alone (ISC), PSI without cells and PSI containing: 106 autologous fibroblasts (PSI-5F), 106
allogenic BM-MSCs (PSI-5M), or 106 of both autologous fibroblasts and allogenic BM-MSCs (PSI-5FM). Islet grafts were retrieved
seven days after transplantation in diabetic mice. Samples were stained with H and E, or labelled with anti-insulin or anti-MPO
antibodies. Black arrows point to islets. B) Quantification of the number of MPO-positive cells per field present on the leukocyte
infiltration of the islet graft. C) Quantification of the insulin-positive area per section present on the islet graft. (**) p<0.01; (***)
p<0.001.
doi: 10.1371/journal.pone.0073526.g004
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The immunomodulatory properties of MSCs when co-
transplanted with islets have been shown in several studies
using well-vascularized sites for graft transplantation [53–55],
where MSC survival may be higher, exerting their protective
effect over longer periods and, therefore, improving graft
viability. Moreover, most of them used allogenic models,
usually under low-dose immunosuppressive therapy during the
first days after transplantation. In this work we have shown the
results of subcutaneous islet transplantation in a xenogenic
model, without using any immunosuppressive drug throughout
the study. Local or systemic administration of successive doses
of BM-MSCs and/or short-term immunosuppression after islet
transplantation, could improve our results. In addition, other cell
types with pro-angiogenic and/or immunomodulatory properties
such as adipose mesenchymal stem cells [56], sertoli cells [57]
and/or endothelial cells [58], could be incorporated into the
graft in order to optimize this model.
Development of autologous insulin-producing cells will surely
become a reality in the future [59], avoiding the use of non-
homologous pancreatic islets. Nevertheless, in spite of their
autologous origin, and taking into account the immunological
basis of type 1 diabetes, the use of immunoregulatory cells
could be a necessary strategy. The use of a bioartificial
endocrine pancreas could be the definitive solution to type 1
diabetes [60], be it by development of “insulin pumps” which
respond automatically to blood glucose levels or be it by
development of tissue-engineered pancreas. In this work, we
have developed a subcutaneous “endocrine pancreas” by
tissue engineering which is able to work physiologically in
immunodeficient mice and, at least temporarily, in
immunocompetent ones. The development of tissue
engineered models, like the PSI, could be a successful strategy
to develop an “artificial endocrine pancreas” by combining
pancreatic islets, or maybe insulin-producing cells, with other
cell types which improve graft revascularization and modulate
the immune response, achieving a physiological-like endocrine
pancreas in an ectopic site without using immunosuppressive
drugs. This system could become a successful strategy in the
field of islet transplantation in the future.
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